Background: The Systolic Hypertension in the Elderly Program (SHEP) demonstrated the benefit of treating isolated systolic hypertension (ISH) in older adults. However, nearly 20% of older adults remain at high risk of heart disease and stroke from untreated ISH. Methods: For the Pittsburgh SHEP cohort, 11- to 14-year death or cardiovascular event rates were compared for active (n = 135) and placebo (n = 133) arms plus normotensive controls (n = 187). Carotid ultrasound and ankle blood pressures were used to identify subclinical atherosclerosis at baseline. Results: Fourteen-year Kaplan-Meier event rate estimates were 58% vs 79% for the active vs placebo groups (P=.001). Eleven-year event rates for the control, active, and placebo groups were 35%, 47%, and 65%, respectively. Compared with controls, the relative risk of an event was 1.6 (95% confidence interval, 1.1-2.4) for the active treatment group and 3.0 (95% confidence interval, 2.1-4.4) for the placebo group. Baseline history of cardiovascular disease was present in 19% of SHEP participants vs 15% of controls (P=32), and subclinical disease (carotid stenosis or low ankle blood pressure) was detected in 33% of SHEP participants vs; 10% of controls (P
CITATION STYLE
Sutton-Tyrrell, K., Wildman, R., Newman, A., & Kuller, L. H. (2003). Extent of Cardiovascular Risk Reduction Associated with Treatment of Isolated Systolic Hypertension. Archives of Internal Medicine, 163(22), 2728–2731. https://doi.org/10.1001/archinte.163.22.2728
Mendeley helps you to discover research relevant for your work.